相关实验视频

Updated: Jan 7, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

预测非霍奇金淋巴瘤癌症治疗相关心脏功能障碍的综合模型

Daniela Bursacovschi¹, Oleg Arnaut^2,3,4, Viorica Ochisor⁵

¹Department of Heart Failure, Public Healthcare Institution-Institute of Cardiology, MD-2025 Chisinau, Moldova.

|December 30, 2025

概括

一个新的预测模型准确地识别了与癌症治疗相关的心脏功能障碍 (CTRCD) 风险的非霍奇金淋巴瘤 (NHL) 患者. 这种工具有助于早期检测和干预NHL患者心脏毒性.

科学领域:

心脏病学心脏病学
在瘤学瘤学.
心脏瘤学 - 心脏瘤学

背景情况:

癌症治疗相关的心脏功能障碍 (CTRCD) 是非霍奇金淋巴瘤 (NHL) 患者的重大并发症.
CTRCD可能导致严重的心血管事件,包括心力衰竭.
早期识别风险患者对于及时干预至关重要.

研究的目的:

在NHL患者中开发和验证CTRCD的预测模型.
评估与化疗相关的早期亚临床心脏变化.

主要方法:

在6个月内对127名成年NHL患者进行了前性队列研究.
使用心声回声学,心肺呼吸运动测试,24小时霍尔特监测和心脏生物标志物 (热素I,NT-proBNP).

主要成果:

对CTRCD的预测模型实现了94.2%的准确性和强大的区分能力 (AUC 0.95).
关键预测因素包括基线SDNNi,心率,多克索鲁比剂量,NT-proBNP,QT间隔,血红蛋白,年龄,左心房体积和心动功能.
较低的心肺储备与增加的CTRCD风险有关.

结论:

开发的模型是评估NHL患者中CTRCD风险的实用和强大的工具.
促进早期检测和管理化疗诱导的心脏毒性.

关键词:

癌症治疗治疗治疗癌症与化疗有关的心脏功能障碍.心脏衰竭是因为心脏衰竭.预测模型预测模型

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...